Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven®) utilization at a large academic medical center

Kassandra Marsh, David Green, Veronica Raco, John Papadopoulos and Tania Ahuja

Abstract

Background: Recombinant factor VIIa (rFVIIa) (Novoseven®) is utilized for the reversal of anticoagulation-associated bleeding and refractory bleeding in cardiac surgery. In August 2015, rFVIIa was transferred from the blood bank to the pharmacy at New York University (NYU) Langone Health. Concordantly, an off-label dosing guideline was developed. The objective of this study was to describe utilization and cost of rFVIIa and assess compliance to our dosing guideline.

Methods: We performed a retrospective, observational review of rFVIIa administrations post-implementation of an off-label dosing guideline. All patients who received rFVIIa between September 2015 and June 2017 were evaluated. For each rFVIIa administration, anticoagulation and laboratory values, indications for use, dosing, ordering and administration times, concomitant blood products, and adverse events were collected. Adverse events included venous thromboembolism, stroke, myocardial infarction, and death due to systemic embolism and mortality. The primary endpoint was the utilization of rFVIIa in accordance with the off-label dosing guideline. Secondary endpoints included hemostatic efficacy of rFVIIa, adverse events, blood products administered, and cost-effectiveness of rFVIIa transition to pharmacy.

Results: A total of 63 patients [pediatric (n = 6), adult (n = 57)] received rFVIIa, with the majority of use for refractory bleeding after cardiac surgery. The utilization of rFVIIa decreased after development of the off-label dosing guideline and transition from blood bank to pharmacy. The total incidence of thromboembolic events within 30 days was 19.6%; 17.6% arterial and 2% venous; 70% of patients with an adverse event were over 70 years of age. Use of rFVIIa reduced the median number of units of blood products administered.

Conclusion: Administration of rFVIIa for cardiac surgery appears to be effective for hemostasis. Transitioning rFVIIa from the blood bank to pharmacy and implementation of a dosing guideline appears to have reduced utilization. Patients receiving rFVIIa should be monitored for thromboembolic events. Elderly patients may be at higher risk for thromboembolic events.

Keywords: cardiac surgery, hemorrhage, hemostasis, rFVIIa, thromboembolism

Introduction

Novoseven® is a recombinant preparation of human factor VIIa (rFVIIa) that facilitates activation of factors X and IX leading to thrombin production, activation of platelets and fibrin, and formation of a clot.1 Human factor VIIa is currently approved for the treatment of bleeding episodes and perioperative management in the setting of hemophilia A or B with inhibitors, congenital factor VII deficiency, and Glanzmann’s thrombasthenia refractory to platelet transfusions. Recombinant factor VIIa has also been evaluated for surgery or trauma-related
bleeding, variceal bleeding, reversal of anticoagulation therapy, and life-threatening bleeding refractory to standard of care.2–9 The optimal dosing strategy of rFVIIa when used for off label indications remains unknown, due to the lack of randomized controlled trials. Furthermore, there are thromboembolic risks associated with utilization of rFVIIa.

The product label for rFVIIa (Novoseven®) indicates a warning for serious arterial and venous thrombotic events.1 Following administration of rFVIIa in clinical trials, thrombotic adverse reactions were seen in 4% of patients with acquired hemophilia and 0.2% of patients with congenital hemophilia.1,10–13 Due to circulation of tissue factor or predisposing coagulopathies, patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, sepsis, concomitant treatment with four-factor prothrombin complex concentrates (4F-PCC), or uncontrolled post-partum hemorrhage may have an increased risk of thromboembolic events.10–13 Caution is advised when administering rFVIIa to patients with an increased risk of thromboembolic events, including patients with coronary heart disease, liver disease, post-operative immobilization, elderly patients, and neonates.10–13 Coagulation parameters such as prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT) have shown to be affected by administration of rFVIIa.14 However, there is no evidence of direct correlation between these parameters and risk of thromboembolic events or achievement of hemostasis.10–13 Monitoring of coagulation parameters may be used in conjunction with clinical signs of a hemostatic response to determine efficacy of rFVIIa, but should not be used alone.

Hemostatic agents are considered high-risk and high-cost medications that require close monitoring and careful dose titrations. Standardization of initial dosing strategies for rFVIIa may help balance the risk of bleeding and thrombosis. Several studies have examined the effects of an off-label dosing guideline in response to concerns of inappropriate use, safety, and cost of rFVIIa, and found that a guideline can serve to decrease the utilization and cost of rFVIIa while not sacrificing patient outcomes.15,16 Likewise, as part of a quality assessment, we sought to evaluate our transition of rFVIIa from the blood bank to pharmacy, and the overall hemostatic efficacy and safety when used according to a developed off-label dosing guideline. These findings were presented as a poster at the International Society on Thrombosis and Haemostasis (ISTH) 64th Annual Scientific and Standardization Committee meeting in Dublin, Ireland in July 2018.

Methods

Institutional guideline

The antithrombotic therapy oversight group at New York University Langone Health (NYULH) developed a guideline in August 2015 to provide dosing recommendations for the use of rFVIIa for off-label indications, based on the available literature and local expert opinion (Table 1). These indications included (1) reversal of oral anticoagulant-associated, life-threatening hemorrhage in patients with documented history of heparin induced thrombocytopenia (HIT) or where 4F-PCC, such as Kcentra®, is contraindicated, (2) reversal of upper gastrointestinal bleeding in the setting of coagulopathy associated with severe liver dysfunction, (3) to limit hematoma expansion in spontaneous intracerebral hemorrhage, (4) treatment of refractory bleeding after cardiac surgery in non-hemophiliac patients, and (5) post-partum hemorrhage refractory to uterotonics. Prescribing of rFVIIa is restricted and requires approval by either the antithrombotic therapy team, an attending physician from critical care, hematology, or obstetrics, or a clinical pharmacotherapy specialist. Recombinant FVIIa dosing (rounded to the nearest milligram if weight-based) is selected according to the guideline indication and is administered with phytonadione in the setting of warfarin-associated intracranial hemorrhage or life-threatening bleeding. The guideline also outlines a strategy for repeat rFVIIa dosing if hemostasis is not achieved after the first administration. Following the implementation of the guideline, rFVIIa was relocated from the blood bank to the pharmacy with a goal to prepare and dispense to the bedside within 30 min of order placed in the electronic medical record. Computerized clinical decision support was enhanced to provide dosing recommendations, dose rounding, and administration considerations, per indication for rFVIIa in the off-label dosing guideline. The dosing protocol also recommends maintaining platelet function above 50,000/mm³ and pH >7.4 for efficacy of rFVIIa. There are no restrictions in place at the time of prescriber ordering for these laboratory
value cutoffs; however, pharmacists were educated on confirmation of these laboratory values prior to verification of the order.

**Study design**
All patients who received any dose of rFVIIa at NYULH post-implementation of the guideline between 1 September 2015 and 30 June 2017 were included. Data collection was obtained through a retrospective electronic medical record review of baseline demographics and past medical history, including venous thromboembolism (VTE), myocardial infarction (MI), stroke, transient ischemic attack (TIA), atrial fibrillation (AF), hypertension, congestive heart failure (CHF), chronic kidney disease, cirrhosis, coagulopathies, hemophilia, congenital factor VII deficiency, anticoagulant use, antiplatelet use, and indication for anticoagulation. A CHA2DS2-VASc score was calculated for patients with a history of AF. For each rFVIIa administration, anticoagulation and laboratory values, indications for use, dosing, ordering and administration times, concomitant blood products within 24 h, and adverse events were collected. Adverse events included VTE, stroke, TIA, death from systemic embolism, MI, hypersensitivity and DIC. Categorical variables were described as frequencies and proportions, and continuous variables were described as medians with interquartile ranges (IQR). Data was managed utilizing Research Electronic Data Capture (REDCap), a secure informatics system designed to support data collection across various research disciplines. Due to the retrospective nature of this observational project done for quality assurance purposes, informed consent was not required and this project was exempt from review by our institutional review board (IRB). All patient data was de-identified and collected in compliance with the hospital’s IRB exempt protocols.

**Outcomes**
The primary outcome was the utilization of rFVIIa at NYULH, defined by the indication and dose utilized during the study period. Secondary endpoints included adherence to the off-label dosing guideline, cost, hemostatic efficacy, and safety. Adherence to the off-label dosing guideline was assessed by reviewing time to administration, dose administered, and overall total cumulative dose. A subgroup analysis to evaluate adherence, efficacy, and safety of rFVIIa according to the off-label dosing guideline in patients with refractory bleeding after cardiac surgery was also conducted. Cost of rFVIIa was assessed utilizing pharmacy purchasing cost from 2016, comparing blood bank data from 2014 to pharmacy utilization in 2016. Blood bank costs were calculated based on the number of purchased vials in 2014, and pharmacy costs were calculated based on vials of rFVIIa documented as administered in 2016. Hemostatic efficacy was defined by evaluation of blood product administration and coagulation patterns within 24 h before and after administration of

| Off-label indication                                      | Dose         | Concomitant medications or repeat dosing               |
|----------------------------------------------------------|--------------|--------------------------------------------------------|
| Warfarin associated intracranial hemorrhage or life-threatening bleeding | Weight < 80 kg: 1 mg Weight > 80 kg: 2 mg | Give with phytonadione 10 mg/50 ml 5% dextrose in water |
| Non-warfarin, target specific oral anticoagulant associated intracranial hemorrhage or life-threatening bleeding | 1 mg         | None                                                   |
| Refractory upper gastrointestinal bleeding in severe liver disease | 40 µg/kg     | May repeat 40 µg/kg 20 min after first dose            |
| Refractory bleeding after cardiac surgery or cardiopulmonary bypass | 20 µg/kg     | May repeat every 20 min to maximum dose of 80 µg/kg    |
| Spontaneous intracerebral hemorrhage                      | 40 µg/kg     | May repeat 40 µg/kg 20 min after first dose            |
| Post-partum hemorrhage refractory to uterotonic            | 50 µg/kg     | May repeat 50 µg/kg 20 min after first dose            |

NYULH, New York University Langone Health.
rFVIIa. Safety of rFVIIa was defined by assessment of VTE, stroke, TIA, death from systemic embolism, MI, hypersensitivity, and DIC within 30 days of rFVIIa administration.

### Results

#### Study population

A total of 63 patients [pediatric \(n = 6\), adult \(n = 57\)] received rFVIIa at NYULH between 1 September 2015 and 30 June 2017. The median age of adult patients was 69 years (IQR 55, 78), and the majority of patients were male (44, 77%). The most common comorbidities included hypertension (36, 63%), atrial fibrillation (17, 30%), and congestive heart failure (14, 25%). A total of 21 (37%) patients had an indication for anticoagulation, which was primarily atrial fibrillation (81%). Further baseline characteristics are described in Tables 2 and 3.

#### Overall utilization of rFVIIa

The utilization of rFVIIa for labeled indications included four (6%) patients with congenital factor VII deficiency, two (3%) patients with bleeding secondary to congenital hemophilia A or B with inhibitors, and one (2%) patient with bleeding secondary to acquired hemophilia (Figure 1). Of those with congenital factor VII deficiency, rFVIIa was used for one bleeding episode and three episodes of perioperative management. The utilization of rFVIIa for indications included on the NYULH off-label dosing guideline included 51 (81%) patients with refractory bleeding after cardiac surgery. Other indications for the use of rFVIIa that were not included on the off-label guideline included one pulmonary hemorrhage, two refractory hemoperitoneum/hemothorax, one episode of oozing of blood during atrial fibrillation ablation, and one undocumented indication. Median weight-based dosing and total dose for each indication is shown in Table 4. All doses for labeled and

| Table 2. Pediatric baseline characteristics. | Table 3. Adult baseline characteristics. |
|---------------------------------------------|------------------------------------------|
| **Pediatric** \(n = 6\)                     | **Adult** \(n = 57\)                     |
| Age, years                                  | Age, years, median (IQR) 69 (55, 78)     |
| Male, \(n\) (%)                             | Male 44 (77)                            |
| Weight, kg                                  | Weight, kg, median (IQR) 76 (67, 88)     |
| Length of stay, days                        | Length of stay, days, median (IQR) 11 (6, 19) |
| All values expressed as median (IQR) unless otherwise noted. | \[All values expressed as \(n\) (%) unless otherwise noted.\] |
off-label guideline indications were similar to the recommended dosing strategies per the rFVIIa package insert and NYULH off-label dosing guideline. In all, 35 (56%) patients received one dose, whereas 28 (44%) patients received more than one dose (Table 5). In 2014, the total cost of rFVIIa purchased by the blood bank was $583,100. After implementation of the off-label dosing guideline and transition to the pharmacy, the total cost of rFVIIa administered in 2016 from the pharmacy was $168,600.

### Utilization of rFVIIa in cardiac surgery

A subgroup analysis was conducted to evaluate adherence, efficacy, and safety of rFVIIa according to the off-label dosing guideline in patients with refractory bleeding after cardiac surgery (Table 6).
In accordance with the NYULH guideline, the dose was delivered and administered within 30 min of order entry in 33 (65%) patients, and doses were administered greater than 20 min apart in 16 (80%) patients. Although 39 (77%) patients received within 10 µg/kg of the 20 µg/kg dose recommended by the NYULH dosing guideline; 9 (18%) patients received a dose greater than 30 µg/kg, and 3 (15%) patients received cumulative doses greater than the recommended maximum dose of 80 µg/kg. In patients who received rFVIIa for refractory bleeding after cardiac surgery, hemostatic efficacy was assessed by blood product administration before and after administration of rFVIIa (Figure 2). The median number of units of cryoprecipitate decreased from 10 (IQR 10, 20) to 5 (IQR 0,10), of fresh frozen plasma from 2 (IQR 0,3) to 0 (IQR 0,2), of platelets from 2 (IQR 1,3) to 1 (IQR 0,2), and of red blood cells from 2 (IQR 0,4) to 1 (IQR 0,2), after the administration of rFVIIa. A total of 10 (20%) patients experienced a thromboembolic event within 30 days of rFVIIa administration (Figure 3). The median number of units of cryoprecipitate decreased from 10 (IQR 10, 20) to 5 (IQR 0,10), of fresh frozen plasma from 2 (IQR 0,3) to 0 (IQR 0,2), of platelets from 2 (IQR 1,3) to 1 (IQR 0,2), and of red blood cells from 2 (IQR 0,4) to 1 (IQR 0,2), after the administration of rFVIIa. A total of 10 (20%) patients experienced a thromboembolic event within 30 days of rFVIIa administration (Figure 3). There was one (2%) occurrence of deep vein thrombosis (DVT) and nine (18%) occurrences of stroke or TIA. The DVT occurred on day 17, in a patient on a heparin bridge to warfarin. Of the nine strokes/TIAs, there were seven ischemic strokes, which occurred on day 0 (n = 2), day 1 (n = 2), day 2 (n = 1), and day 3 (n = 2) post rFVIIa administration. Only one out of these seven patients had a prior indication for anticoagulation, which had not been restarted due to thrombocytopenia and risk of bleeding post procedure. Out of the two TIAs that occurred, one occurred on day 2 in a patient that had atrial fibrillation, and one occurred day 12 post rFVIIa. Five (50%) adverse events occurred in patients receiving more than one dose, and seven (70%) occurred in patients over 70 years of age. There were no occurrences of
Discussion

We found that implementation of an off-label dosing guideline and the transition of rFVIIa from the blood bank to the pharmacy appeared to offer a safe and cost-effective strategy for the management of this high-risk, high-cost hemostatic agent. Previously, Owen et al. demonstrated that implementation of a guideline for the use of rFVIIa led to an increase in appropriate prescribing, decrease in rFVIIa utilization, and a decrease in costs.15 They found that the mean total dosage of rFVIIa administered per patient before implementation of the guideline was 81.8 µg/kg compared with 45.3 µg/kg after guideline implementation, and there was an overall 49% decrease in rFVIIa administered monthly.15 This led to a decrease of $110,014 in the semiannual costs of rFVIIa.15 Furthermore, the implementation of a guideline did not show to adversely affect patient outcomes.15 In addition, Trueg et al. conducted an evaluation of rFVIIa and PCC orders before and after implementation of a pharmacist-directed blood factor stewardship program.19 Mortality at 28 days was similar between groups (53.9% versus 50%, \( p = 0.77 \)); however, there was an annual cost savings of $375,539, primarily through a significant reduction in rFVIIa utilization.19 Similar to these studies, we found a decrease in rFVIIa administered with the implementation of an off-label dosing guideline, leading to a $414,500 decrease in the annual costs of rFVIIa. This may have been attributed to the recommendation for lower initial starting doses, the use of dose rounding, and purchasing multiple vial strengths to limit waste.

The majority of rFVIIa use at NYULH was for refractory bleeding after cardiac surgery or cardiopulmonary bypass. A number of previously published reports have suggested that rFVIIa is appropriate for rescue therapy of massive bleeding in cardiovascular surgery patients.9,20–29 The NYULH off-label guideline recommends a dose of 20 µg/kg for this indication, followed by repeat dosing of 20 µg/kg to a maximum cumulative dose of 80 µg/kg if needed. This recommendation was implemented in order to mitigate potential harm associated with the use of rFVIIa, without compromising efficacy. Although previous studies have used higher doses in this patient population, the antithrombotic therapy oversight group along with cardiac surgery at NYULH recommended a lower initial dose, with the ability to repeat dosing if refractory bleeding persisted.6,9,20,29 In our evaluation, 77% of doses were according to the NYULH guideline, 4%
were lower than recommended, and 18% were higher than recommended.

Transfusion of blood after cardiac surgery has been associated with decreased long-term survival, and there is an 8-fold increase in the risk of death with administration of 5 units of packed red blood cells (pRBC). Transfusion-related acute lung injury and transfusion-associated circulatory overload contribute significantly to this mortality in post-operative cardiac surgery patients. We found that administration of rFVIIa reduced the median number of units of blood products administered, a finding previously reported in the literature. In one retrospective, observational review, the units of pRBC and platelets administered decreased by an average of 4.28 ± 6.74 units and 5.15 ± 12.9 units, respectively, after administration of rFVIIa. The reduction in units of pRBC administered was significant among dosing quartiles >30 µg/kg, but not in the dosing quartile <30 µg/kg. As the amount of blood products administered prior to rFVIIa was lower in our study, we believe that lower doses of rFVIIa for refractory bleeding in cardiac surgery may be a reasonable approach. Although rFVIIa has been shown to be effective for managing massive blood loss in cardiovascular patients, treatment using rFVIIa carries a significant risk of thromboembolic events. In our study, the total incidence of thromboembolic events within 30 days was 19.6%, with 17.6% being arterial events and 2% being venous events. Seven (70%) patients with an adverse event were over 70 years of age. This finding is higher than previous reported literature, which reports 10.2% total thromboembolic, 5.5% arterial, and 5.3% venous events. However, this is consistent with literature supporting higher thromboembolic event rates in patients over 65 years of age. In addition, the utilization of rFVIIa in cardiac surgery patients may have predisposed these patients to a higher risk for arterial thromboembolic events, as the majority of anticoagulation therapy was administered due to underlying atrial fibrillation.

Our study is limited by its retrospective design and moderate sample size. In addition, although blood product administration pre- and post- rFVIIa were collected, the decision to administer these products was up to the cardiac surgery team. In addition, the data available for the indications for rFVIIa from the blood bank could not be assessed due to lack of documentation of dose or indication in the administration record. Therefore, although we did see a decrease in cost after the transition to the pharmacy, we cannot identify if this decrease is due to the oversight by pharmacy, creation of the dosing guideline, chance, or other reasons. Lastly, patients in our study were not managed according to a standardized blood product administration protocol, and overall use of blood products was lower than reported in similar previous literature.

Conclusion
Implementation of an off-label dosing guideline, enhanced computerized clinical decision support in the electronic medical record, and transition of rFVIIa from the blood bank to the pharmacy appears to have reduced costs associated with the use of rFVIIa. Administration of rFVIIa at the recommended dosage for cardiac surgery appears to be an effective strategy for hemostasis, as determined by reduction in blood product administration. Our analysis supports previously reported literature regarding standardization of an approach to the use of high-risk hemostatic agents. As we found that the majority of thromboembolic events occurred in patients over 70 years of age, we recommend judicious use of rFVIIa, and careful monitoring in this population. Larger, prospective studies are needed to determine the optimal use and dosage of rFVIIa. In addition, strategies, such as the use of other hemostatic agents such as four-factor prothrombin complex concentrates (4F-PCC) may be warranted for the management of refractory bleeding post cardiac surgery. Comparing hemostatic agents such as rFVIIa to 4F-PCC, to determine the optimal agent and dose may be necessary, to determine the most safe, cost-effective agent.

Conflict of interest statement
The authors declare that there is no conflict of interest.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Tania Ahuja https://orcid.org/0000-0003-1833-4124
References

1. Novoseven RT (coagulation factor VIIa recombinant) [package insert]. Princeton, NJ: NovoNordisk; 2010.

2. Levi M, Peters M and Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883–890.

3. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127: 1123–1130.

4. Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008; 47: 1604–1614.

5. Dager WE, King H, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006; 26: 1091–1098.

6. Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120: 21–27.

7. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127–2137.

8. Lavigne-Lissalde G, Aya AG, Mercier FJ, et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost 2015; 13: 520–529.

9. Diprose P, Herbertson MJ, O’Shaughnessy D, et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95: 596–602.

10. Parameswaran R, Shapiro AD, Gill JC, et al. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the hemophilia and thrombosis research society registry. Haemophilia 2005; 11: 100–106.

11. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa study group. Haemophilia 1998; 4: 790–798.

12. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773–778.

13. Lusher JM. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996; 26(Suppl. 1): 124–130.

14. Allen GA, Monroe DM, Roberts HR, et al. The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S3–S7.

15. Owen PS, Golightly LK, MacLaren R, et al. Formulary management of recombinant factor VIIa at an academic medical center. Ann Pharmacother 2008; 42: 771–776.

16. Bain J, Lewis D, Bernard A, et al. Implementation of an off-label recombinant factor VIIa protocol for patients with critical bleeding at an academic medical center. J Thromb Thrombolysis 2014; 38: 447–452.

17. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272.

18. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.

19. Trueg AO, Lowe C and Kiel PJ. Clinical outcomes of a pharmacy-led blood factor stewardship program. Am J Ther 2017; 24: e643–e647.

20. Omar HR, Enten G, Karlnoski R, et al. Recombinant activated factor VII significantly reduces transfusion requirements in cardiothoracic surgery. Drugs R D 2015; 15: 187–194.

21. Karimi A, Daigle SS, Smith WB, et al. Efficacy and safety of recombinant factor VII as rescue for severe perioperative bleeding in heartmate II recipients. J Card Surg 2015; 30: 500–505.

22. Chapman SA, Irwin ED, Abou-Karam NM, et al. Comparison of 3-factor prothrombin complex
concentrate and low-dose recombinant factor VIIa for warfarin reversal. *World J Emerg Surg* 2014; 9: 27.

23. Uber WE, Toole JM, Stroud MR, et al. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes. *J Thorac Cardiovasc Surg* 2011; 141: 1469–1477.e1462.

24. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. *Transfusion* 2005; 45: 26–34.

25. Vanek T, Straka Z, Hrabak J, et al. Use of recombinant activated factor VII in cardiac surgery for an effective treatment of severe intractable bleeding. *Jpn Heart J* 2004; 45: 855–860.

26. Raivio P, Suojaranta-Ylinen R and Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. *Ann Thorac Surg* 2005; 80: 66–71.

27. Hyllner M, Houltz E and Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. *Eur J Cardiothorac Surg* 2005; 28: 254–258.

28. von Heymann C, Redlich U, Jain U, et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery—a retrospective analysis of safety and efficacy. *Crit Care Med* 2005; 33: 2241–2246.

29. Masud F, Bostan F, Chi E, et al. Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes. *J Cardiothorac Vasc Anesth* 2009; 23: 28–33.

30. Skeate RC and Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. *Curr Opin Hematol* 2007; 14: 682–687.

31. O’Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. *JAMA* 2006; 295: 293–298.

32. Levi M, Levy JH, Andersen HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. *N Engl J Med* 2010; 363: 1791–1800.

33. Arnékian V, Camous J, Fattal S, et al. Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. *Interact Cardiovasc Thorac Surg* 2012; 15: 382–389.

34. Ortmann E, Besser MW, Sharples LD, et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. *Anesth Analg* 2015; 121: 26–33.

35. Cappabianca G, Mariscalco G, Biancari F, et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. *Crit Care* 2016; 20: 5.